Literature DB >> 19427294

Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas.

Lu Q Le1, Tracey Shipman, Dennis K Burns, Luis F Parada.   

Abstract

The tumor predisposition disorder neurofibromatosis type I (NF1) is one of the most common genetic disorders of the nervous system. It is caused by mutations in the Nf1 tumor-suppressor gene, which encodes a GTPase-activating protein (GAP) that negatively regulates p21-RAS. Development of malignant nerve tumors and neurofibromas occurs frequently in NF1. However, little is known about the molecular mechanisms mediating the initiation and progression of these complex tumors, or the identity of the specific cell type that gives rise to dermal or cutaneous neurofibromas. In this study, we identify a population of stem/progenitor cells residing in the dermis termed skin-derived precursors (SKPs) that, through loss of Nf1, form neurofibromas. We propose that SKPs, or their derivatives, are the cell of origin of dermal neurofibroma. We also provide evidence that additional signals from nonneoplastic cells in the tumor microenvironment play essential roles in neurofibromagenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19427294      PMCID: PMC2737469          DOI: 10.1016/j.stem.2009.03.017

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  48 in total

1.  Skin-derived precursors generate myelinating Schwann cells for the injured and dysmyelinated nervous system.

Authors:  Ian A McKenzie; Jeff Biernaskie; Jean G Toma; Rajiv Midha; Freda D Miller
Journal:  J Neurosci       Date:  2006-06-14       Impact factor: 6.167

2.  Analysis of the neurogenic potential of multipotent skin-derived precursors.

Authors:  Karl J L Fernandes; Nao R Kobayashi; Conor J Gallagher; Fanie Barnabé-Heider; Anne Aumont; David R Kaplan; Freda D Miller
Journal:  Exp Neurol       Date:  2006-05-05       Impact factor: 5.330

Review 3.  Neurofibromin: a general outlook.

Authors:  A B Trovó-Marqui; E H Tajara
Journal:  Clin Genet       Date:  2006-07       Impact factor: 4.438

4.  Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.

Authors:  Feng-Chun Yang; Shi Chen; Travis Clegg; Xiaohong Li; Trent Morgan; Selina A Estwick; Jin Yuan; Waleed Khalaf; Sarah Burgin; Jeff Travers; Luis F Parada; David A Ingram; D Wade Clapp
Journal:  Hum Mol Genet       Date:  2006-07-11       Impact factor: 6.150

Review 5.  Neurofibromatosis 1: from lab bench to clinic.

Authors:  Beth Ann Ward; David H Gutmann
Journal:  Pediatr Neurol       Date:  2005-04       Impact factor: 3.372

Review 6.  Interpreting epithelial cancer biology in the context of stem cells: tumor properties and therapeutic implications.

Authors:  Stanley J Miller; Robert M Lavker; Tung-Tien Sun
Journal:  Biochim Biophys Acta       Date:  2005-09-25

7.  Isolation of skin-derived precursors (SKPs) and differentiation and enrichment of their Schwann cell progeny.

Authors:  Jeffrey A Biernaskie; Ian A McKenzie; Jean G Toma; Freda D Miller
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

Review 8.  Neurofibromatosis 1.

Authors:  Rosalie E Ferner
Journal:  Eur J Hum Genet       Date:  2006-09-06       Impact factor: 4.246

9.  Isolation and characterization of multipotent skin-derived precursors from human skin.

Authors:  Jean G Toma; Ian A McKenzie; Darius Bagli; Freda D Miller
Journal:  Stem Cells       Date:  2005 Jun-Jul       Impact factor: 6.277

10.  Identification of human brain tumour initiating cells.

Authors:  Sheila K Singh; Cynthia Hawkins; Ian D Clarke; Jeremy A Squire; Jane Bayani; Takuichiro Hide; R Mark Henkelman; Michael D Cusimano; Peter B Dirks
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

View more
  78 in total

Review 1.  Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms.

Authors:  Steven L Carroll
Journal:  Acta Neuropathol       Date:  2011-12-11       Impact factor: 17.088

Review 2.  Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression.

Authors:  Karl Staser; Feng-Chun Yang; D Wade Clapp
Journal:  Annu Rev Pathol       Date:  2011-11-07       Impact factor: 23.472

Review 3.  Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems.

Authors:  Fausto J Rodriguez; Andrew L Folpe; Caterina Giannini; Arie Perry
Journal:  Acta Neuropathol       Date:  2012-02-12       Impact factor: 17.088

Review 4.  Glial versus melanocyte cell fate choice: Schwann cell precursors as a cellular origin of melanocytes.

Authors:  Igor Adameyko; Francois Lallemend
Journal:  Cell Mol Life Sci       Date:  2010-05-09       Impact factor: 9.261

5.  Perioperative management of neurofibromatosis type 1.

Authors:  Charles J Fox; Samir Tomajian; Aaron J Kaye; Stephanie Russo; Jacqueline Volpi Abadie; Alan D Kaye
Journal:  Ochsner J       Date:  2012

Review 6.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

7.  The development of cutaneous neurofibromas.

Authors:  Eeva-Mari Jouhilahti; Sirkku Peltonen; Tom Callens; Elina Jokinen; Anthony M Heape; Ludwine Messiaen; Juha Peltonen
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

8.  Preclinical therapeutic efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral nerve sheath tumors.

Authors:  Vincent Chau; S Kyun Lim; Wei Mo; Chiachi Liu; Amish J Patel; Renée M McKay; Shuguang Wei; Bruce A Posner; Jef K De Brabander; Noelle S Williams; Luis F Parada; Lu Q Le
Journal:  Cancer Res       Date:  2013-11-27       Impact factor: 12.701

9.  Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1.

Authors:  Nandina Paria; Tae-Joon Cho; In Ho Choi; Nobuhiro Kamiya; Kay Kayembe; Rong Mao; Rebecca L Margraf; Gerlinde Obermosser; Ila Oxendine; David W Sant; Mi Hyun Song; David A Stevenson; David H Viskochil; Carol A Wise; Harry K W Kim; Jonathan J Rios
Journal:  J Bone Miner Res       Date:  2014-12       Impact factor: 6.741

Review 10.  Optimizing biologically targeted clinical trials for neurofibromatosis.

Authors:  David H Gutmann; Jaishri O Blakeley; Bruce R Korf; Roger J Packer
Journal:  Expert Opin Investig Drugs       Date:  2013-02-21       Impact factor: 6.206

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.